niagenbioscience.com (NAGE): Operating Profitability

ChromaDex Corporation (NAGE) - corporate logo

The operating profit-to-revenue ratio for Chromadex Corp (NAGE) reflects market expectations, with the current level standing at 2.30. This trend is driven by patent leadership in the Nicotinamide Riboside sector, which creates long-term B2B customer lock-in. Robotic supplement production in sterile zones further enhances efficiency. Meanwhile, the company relies on external chemical synthesis of components, ensuring strict quality control without owning the manufacturing plants.

NAGE - ChromaDex Operating Profit Ratio over the range 03/20/2025 - 11/19/2026

Analytical breakdowns for Chromadex Corp

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company valuation:NAGE, ChromaDex
Finished products of Niagen

Chromadex Corp (NAGE) is scaling its presence in the biohacking segment through the retail expansion of NAD+ supplements. The operating margin reflects the efficiency of profit generation from core operations before accounting for financial expenses and taxes. Analyzing the operating margin allows for an assessment of the business model's real profitability, excluding debt load. Growth in this ratio confirms cost optimization amid increasing sales, while a stable figure indicates the company's fundamental resilience.

Competitor analysis for Chromadex Corp

ISRG (intuitive.com) - Operating Margin|Return on Sales by Operating Profit DHR (Danaher Corp.)|Operating Sales Margin BDX (Becton, Dickinson and Company)|Operating Profit Ratio STE|Operating Profitability West Pharma WST|Profitability of Operations Baxter (BAX)|MASI - Operating Profitability|Profitability of Operations Stevanato Group Corp STVN|TFX: Operating Margin|Operating Sales Margin Merit Medical Systems|Operating Profitability Envista Holdings Corp|Operating Sales Margin ICU Medical Corp (ICUI)|Operating Profitability DENTSPLY SIRONA Inc. (XRAY)|Operating Sales Margin LeMaitre LMAT|Operating Margin ATRC (atricure.com)|Operating Margin staar.com STAA|ZimVie Inc - Operating Margin|Operating Return on Sales AngioDynamics|CERS (Cerus Corp) - Operating Sales Margin|Alpha Teknova, Inc. - Operating Profit Rate|MGRM (Monogram Orthopedics Inc.) - Operating Margin|STSS: Operating Profit Rate|Operating Sales Margin INFU (InfuSystem Holdings)|Utah Medical Products, Inc. - Return on Sales by Operating Profit|Operating Margin KRMD (korumedical.com)|Profitability of Operations Nyxoah, S.A. (NYXH)|MBOT - Operating Profitability|PDEX (Pro-Dex, Inc.) - Return on Sales by Operating Profit|ZTEK (Zentek Ltd) - Operating Sales Margin|ELUT - Profitability of Operations|MLSS (Milestone Scientific Corporation) - Operating Margin|Return on Sales by Operating Profit NXGL (NEXGEL, Inc.)|Operating Margin RVP|Operating Sales Margin Harvard Bioscience HBIO|Operating Margin FEMY (Femasys Corporation)|MHUA - Operating Sales Margin|POAI - Operating Profitability|Callan JMB (CJMB) - Operating Sales Margin|ATRI: Operating Margin|NURO - Profitability of Operations